buy Faricimab | Faricimab supplier | purchase Faricimab | Faricimab cost | Faricimab manufacturer | order Faricimab

Size	Availability	Price(USD)	VIP Price (USD)	Quantity
There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Size

Availability

Price(USD)

VIP Price (USD)

Quantity

There is no price information at the moment, you can send an inquiry,and we will reply to you as soon as possible.

Product Overview

Product Name	Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)
CAS	1607793-29-2
Storage condition	store at -20°C

Product details

Faricimab is a pioneering humanized bispecific antibody that targets both VEGF-A and Ang-2, offering a dual inhibition approach for retinal diseases like DME and nAMD. By inhibiting VEGF-A, it reduces endothelial cell proliferation and vascular permeability, while blocking Ang-2 is believed to enhance vascular stability and counteract VEGF-A effects. Faricimab has demonstrated a significant reduction in annual injections compared to other anti-VEGF treatments, with a comparable efficacy and safety profile, positioning it as a valuable treatment option for patients with retinal diseases.

Related literature

Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME[J].

PMID: 38233896 PMCID: PMC10795384 DOI: 10.1186/s40942-024-00525-9

Pharmaceutical compounding and storage of faricimab in a syringe for intravitreal injection do not impair stability and bi-specific binding properties[J].

PMID: 37936232 PMCID: PMC10631190 DOI: 10.1186/s40942-023-00507-3

Delineating effects of angiopoietin-2 inhibition on vascular permeability and inflammation in models of retinal neovascularization and ischemia/reperfusion[J].

PMID: 37377777 PMCID: PMC10291265 DOI: 10.3389/fncel.2023.1192464

Sorry, no related items

History

CLA1508

Anti-Human VEGFAxANGPT2 (Faricimab; RG7716)

1607793-29-2 95+%